Journal article
Anakinra reduces blood pressure and renal fibrosis in one kidney/DOCA/salt-induced hypertension
YH Ling, SM Krishnan, CT Chan, H Diep, D Ferens, J Chin-Dusting, BK Kemp-Harper, CS Samuel, TD Hewitson, E Latz, A Mansell, CG Sobey, GR Drummond
Pharmacological Research | ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD | Published : 2017
Open access
Abstract
Objective To determine whether a clinically-utilised IL-1 receptor antagonist, anakinra, reduces renal inflammation, structural damage and blood pressure (BP) in mice with established hypertension. Methods Hypertension was induced in male mice by uninephrectomy, deoxycorticosterone acetate (2.4 mg/d, s.c.) and replacement of drinking water with saline (1K/DOCA/salt). Control mice received uninephrectomy, a placebo pellet and normal drinking water. 10 days post-surgery, mice commenced treatment with anakinra (75 mg/kg/d, i.p.) or vehicle (0.9% saline, i.p.) for 11 days. Systolic BP was measured by tail cuff while qPCR, immunohistochemistry and flow cytometry were used to measure inflammatory ..
View full abstractGrants
Awarded by Deutscher Akademischer Austauschdienst
Funding Acknowledgements
This work was supported by grants from the National Health and Medical Research Council of Australia (NHMRC; APP1062721) and the Group-of-Eight Australia (Go8)/German Academic Exchange Service (DAAD) Joint Research-Cooperation Scheme. GRD, CGS and CSS are supported by Senior Research Fellowships from the National Health and Medical Research Council of Australia (NHMRC; ID Nos. APP1006017, APP1079467 and APP1041766, respectively). YHL is supported by an Australian Postgraduate Award (APA) while SMK is supported by a Monash Graduate Scholarship (ID No. 5129593). None of these funding sources had any role in the writing of the report or in the decision to submit the article for publication.